Deferred Tax Assets, Valuation Allowance of Actinium Pharmaceuticals, Inc. from 31 Dec 2011 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Actinium Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2011 to 31 Dec 2024.
  • Actinium Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2024 was $101,613,000, a 12% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Actinium Pharmaceuticals, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $101,613,000 +$11,048,000 +12% 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q4 2023 $90,565,000 +$14,472,000 +19% 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q4 2022 $76,093,000 +$13,494,000 +22% 31 Dec 2022 10-K 29 Mar 2024 2023 FY
Q4 2021 $62,599,000 +$6,425,000 +11% 31 Dec 2021 10-K 31 Mar 2023 2022 FY
Q4 2020 $56,174,000 +$6,237,000 +12% 31 Dec 2020 10-K 25 Mar 2022 2021 FY
Q4 2019 $49,937,000 +$3,542,472 +7.6% 31 Dec 2019 10-K 31 Mar 2021 2020 FY
Q4 2018 $46,394,528 +$5,500,214 +13% 31 Dec 2018 10-K 08 May 2020 2019 FY
Q4 2017 $40,894,314 -$6,908,066 -14% 31 Dec 2017 10-K 15 Mar 2019 2018 FY
Q4 2016 $47,802,380 +$18,892,197 +65% 31 Dec 2016 10-K 16 Mar 2018 2017 FY
Q4 2015 $28,910,183 +$6,043,843 +26% 31 Dec 2015 10-K 16 Mar 2017 2016 FY
Q4 2014 $22,866,340 +$4,982,042 +28% 31 Dec 2014 10-K 11 Mar 2016 2015 FY
Q4 2013 $17,884,298 +$2,078,578 +13% 31 Dec 2013 10-K 16 Mar 2015 2014 FY
Q4 2012 $15,805,720 +$1,970,237 +14% 31 Dec 2012 10-K 28 Feb 2014 2013 FY
Q4 2011 $13,835,483 31 Dec 2011 10-K 29 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.